![Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/ddi/2020/apixaban-featured.jpg)
Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation
![These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS. ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012 These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS. ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=apixa-2.5mg-label.jpg.jpg&id=690559)
These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS. ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012
![Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications | Leaders in Pharmaceutical Business Intelligence (LPBI) Group Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications | Leaders in Pharmaceutical Business Intelligence (LPBI) Group](https://i0.wp.com/pharmaceuticalintelligence.com/wp-content/uploads/2014/05/eliquis-1.jpeg)